Oriol Mirallas, Clinical Fellow in the Investigational Cancer Therapeutics (ICT) Department at the University of Texas MD Anderson Cancer Center, shared a post on LinkedIn about a paper he co-authored with colleagues published in npj Precision Oncology:
“Just published Nature Magazine – Springer Nature
First ESCAT scale for better selecting targeted treatment for patients with gliomas.
Titanic effort of many people involved from 8 centers in Spain:
- Hospital Universitari
- Vall d’Hebron Vall d’Hebron Institute of Oncology (VHIO)
- Hospital 12 de Octubre
- Hospital Clínic de Barcelona
- Hospital de la Santa Creu i Sant Pau
- Catalan Institute of Oncology
- Hospital del Mar
- Hospital Universitario Ramón y Cajal to analyze the impact of NGS in patients with brain tumors.
Summary:
- 541 Patients
- Multicentric study
- Longer PFS and OS for patients harboring Tier 1&2 molecular alterations ESCAT
- ORR 33% non-GBM
- ORR 17% GBM
Thanks to all patients from all centers and families involved!
Big thanks to Maria Vieito Villar for trusting me to move this forward, and to the rest of co-authors, who did an extraordinary job and without whom this project would not have been possible.”
Title: Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study
Authors: Oriol Mirallas, Fiorella Ruiz-Pace, Gabriel Velilla, Diego Gómez-Puerto, Teresa Gorria, Jesus Yaringaño, Álvaro Martínez-Monino, Daniel López-Valbuena, Maria Angeles Vaz, Ainhoa Hernandez, Elena Martínez-Saez, Maria Aguado Sorolla, Maria Castro-Henriques, Julia Lostes Bardaji, Antonio Di Muzio, Oscar Gallego, María Martínez-García, Marta Domenech, Joan Carles, Carmen Balaña, Estela Pineda, Rodrigo Dienstmann, Juan Manuel Sepúlveda, Maria Vieito
You can read the full article in npj Precision Oncology.
More posts about Gliomas.